Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Total Income in Q2 FY25 stood at Rs. 532.18 crore
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Subscribe To Our Newsletter & Stay Updated
